Terminated PHASE3 INTERVENTIONAL 2-arm NCT01541202

Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients

A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure

Sponsor: Zensun Sci. & Tech. Co., Ltd.

Conditions Chronic Heart Failure

Interventions Placebo rhNRG-1

Updated 7 times since 2017 Last updated: Dec 19, 2017 Started: Feb 29, 2012 Primary completion: Aug 31, 2017 Completion: Aug 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor has designed another study to replace the current study

Other terminated trials from Zensun Sci. & Tech. Co., Ltd.

More terminations from Zensun Sci. & Tech. Co., Ltd.

Other Chronic Heart Failure trials with similar outcome

Browse all Chronic Heart Failure trials

This PHASE3 trial investigates Chronic Heart Failure and is currently terminated or withdrawn. Zensun Sci. & Tech. Co., Ltd. leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Jan 2018 — Jun 2018 [monthly]

Terminated PHASE3

Status: Unknown Status → Terminated
Jan 2017 — Jan 2018 [monthly]

Unknown Status PHASE3

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zensun Sci. & Tech. Co., Ltd.

Data source: Zensun Sci. & Tech. Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Dalian, China , Daqing, China , Fuzhou, China , Guangzhou, China , Haerbin, China and 19 more locations